Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Megestrol · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) with a high fat meal |
| B | ACTIVE_COMPARATOR | Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) following an overnight fast |
| Name | Type | Description |
|---|---|---|
| Megestrol acetate oral suspension 625 mg/5 mL | DRUG | Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal |
Inclusion Criteria: * Body weight ranging from 60-100 kg (132-220 lbs) and body mass index ≥18 and ≤32 * Healthy Exclusion Criteria: * History of or any current medical conditions that could interfere with drug consumption, absorption, distribution, metabolism (eg. CYP450 inducers or inhibitors),...
Megestrol is a small molecule being studied for pharmacokinetics, specifically to evaluate the effect of food on its absorption. It is in Phase 1 clinical development for this purpose. The drug is being developed by BrainsWay Ltd. and is in the gastrointestinal therapeutic area.
Megestrol does not have a specified molecular target or target class. It is a small molecule being studied for its pharmacokinetic properties, particularly how food affects its absorption. The drug is in Phase 1 clinical development.
Megestrol is being developed by BrainsWay Ltd., a company traded under the ticker BWAY. The drug is in Phase 1 clinical development for pharmacokinetic studies. BrainsWay Ltd. is conducting research on this small molecule in the gastrointestinal therapeutic area.
Megestrol is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied for pharmacokinetics. The drug has completed one Phase 1 trial, which evaluated the effect of food on its absorption.
Megestrol has one completed clinical trial, NCT00638079, titled 'Evaluating the Effect of Food on Absorption of Megace ES'. This Phase 1 study enrolled 24 healthy male volunteers in Canada and was active-controlled. The trial focused on pharmacokinetics, bioavailability, and absorption.
Megestrol is the drug being studied, and the clinical trial NCT00638079 evaluates 'Megace ES', which is a formulation of megestrol. The trial assesses the effect of food on the absorption of this formulation. Megestrol is in Phase 1 development for pharmacokinetics.